Thelansis

 Secondary progressive multiple sclerosis (SMPS) is the relapsing-remitting stage of multiple sclerosis followed by a phase of insidious worsening of neurologic function independent from relapses. SPMS is traditionally classified as a distinct subtype of MS; there is overlap in their pathological features and disease mechanisms. The transition from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (SPMS) remains a clinical challenge owing to the heterogeneous course of the disease, indistinct disease progression, and lack of availability of validated biomarkers and diagnostic tools. There was a general agreement that the current treatment goal for SPMS is to halt disease progression and prevent the worsening of symptoms. The management of SPMS includes pharmacological management of the disease, in other words, drugs with a relapsing indication or symptomatic drugs; and non-pharmacological management, in other words, rehabilitation and physiotherapy ...